---
figid: PMC5008283__oncotarget-07-21259-g001
figtitle: 'Beyond evidence-based data: scientific rationale and tumor behavior to
  drive sequential and personalized therapeutic strategies for the treatment of metastatic
  renal cell carcinoma'
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC5008283
filename: oncotarget-07-21259-g001.jpg
figlink: /pmc/articles/PMC5008283/figure/F1/
number: F1
caption: RCC is a highly vascularized tumor type. The chronic angiogenesis is required
  for growth of these tumors. Under normal conditions HIF (hypoxia inducible factor)
  is constitutively degraded. HIF promotes transcription of gene involved in the angiogenesis-pathway
  and tumor progression such as VEGF, PDGF and TGF-alfa. Inactivation of the von Hippel-Lindau
  (VHL) gene leads to accumulation of HIF transcription factors and subsequent activation
  of several mediator of angiogenesis. Also the activation of the mammalian target
  of rapamycin (mTOR) signaling pathway may result in HIF accumulation. Temsirolimus
  and everolimus are kinase inhibitors of mTOR complex 1 (mTORC1); bevacizumab is
  a humanized anti-VEGF monoclonal antibody; sorafenib, sunitinib, pazopanib and axitinib
  are multikinase inhibitor (TKIs) of growth factor receptors involved in the activation
  of angiogenesis-related pathways.
papertitle: 'Beyond evidence-based data: scientific rationale and tumor behavior to
  drive sequential and personalized therapeutic strategies for the treatment of metastatic
  renal cell carcinoma.'
reftext: Lorena Incorvaia, et al. Oncotarget. 2016 Apr 19;7(16):21259-21271.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9345762
figid_alias: PMC5008283__F1
figtype: Figure
redirect_from: /figures/PMC5008283__F1
ndex: ecf7b36f-df08-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5008283__oncotarget-07-21259-g001.html
  '@type': Dataset
  description: RCC is a highly vascularized tumor type. The chronic angiogenesis is
    required for growth of these tumors. Under normal conditions HIF (hypoxia inducible
    factor) is constitutively degraded. HIF promotes transcription of gene involved
    in the angiogenesis-pathway and tumor progression such as VEGF, PDGF and TGF-alfa.
    Inactivation of the von Hippel-Lindau (VHL) gene leads to accumulation of HIF
    transcription factors and subsequent activation of several mediator of angiogenesis.
    Also the activation of the mammalian target of rapamycin (mTOR) signaling pathway
    may result in HIF accumulation. Temsirolimus and everolimus are kinase inhibitors
    of mTOR complex 1 (mTORC1); bevacizumab is a humanized anti-VEGF monoclonal antibody;
    sorafenib, sunitinib, pazopanib and axitinib are multikinase inhibitor (TKIs)
    of growth factor receptors involved in the activation of angiogenesis-related
    pathways.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PTEN
  - AKT1
  - AKT2
  - AKT3
  - HIF1A
  - EPAS1
  - HIF3A
  - VHL
  - ARNT
  - ARNT2
  - BMAL1
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Pten
  - Akt
  - sima
  - Vhl
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - Temsirolimus
  - Pazopanib
  - Cancer
---
